CAS 94359-12-3

C22 Sphingomyelin (d18:1/22:0)

CAS : 94359-12-3

C22 Sphingomyelin, associated with HCV and hepatic steatosis, varies in breast cancer cells compared to C16 variant.

Formule : C₄₅H₉₁N₂O₆P

Couleur et forme : Solid

Masse moléculaire : 787.19

Ref: TM-T36860

N-Docosanoyl-D-erythro-sphingosylphosphorylcholine

CAS : 94359-12-3

Formule : C45H91N2O6P

Degré de pureté : >98%

Couleur et forme : Solid

Masse moléculaire : 787.19

Ref: 48-56-1532

c22 Sphingomyelin (d18:1/22:0)

CAS : 94359-12-3

C22 Sphingomyelin (d18:1/22:0) is a type of sphingolipid that has been studied for its potential in cancer treatment. It has been shown to have anticancer properties by inducing apoptosis or programmed cell death in cancer cells. In addition, it can inhibit the activity of certain kinases, which are enzymes that play a role in tumor growth and progression. This sphingomyelin analog has been tested on human and Chinese hamster ovary cells and has demonstrated efficacy against various types of tumors, including breast and colon cancer. Furthermore, it has been found to be an inhibitor of hyaluronan-mediated motility receptor, which is involved in cancer cell migration and invasion. C22 Sphingomyelin (d18:1/22:0) is a promising candidate for the development of kinase inhibitors for the treatment of cancer.

Formule : C₄₅H₉₁N₂O₆P

Degré de pureté : Min. 95%

Masse moléculaire : 787.2 g/mol

Ref: 3D-UDA35912